Core Insights - The company, Nocera Biopharma-U (688428), is making significant progress in clinical research, partnerships, and product commercialization in 2026. Clinical Development Progress - ICP-488 (highly selective TYK2 inhibitor) has completed patient enrollment for its Phase III clinical trial for psoriasis, with a total of 383 patients enrolled, marking a key clinical milestone [2] - Soficitinib (TYK2 inhibitor) has completed patient enrollment for its Phase III registration trial for moderate to severe atopic dermatitis, with accelerated trials for indications like vitiligo and nodular prurigo [2] - Obinutuzumab (BTK inhibitor) has completed its Phase III clinical study for idiopathic thrombocytopenic purpura (ITP) and is expected to submit a New Drug Application (NDA) in the first half of 2026; a Phase IIb study for systemic lupus erythematosus (SLE) has met its primary endpoint, with a Phase III trial set to begin soon [3] - BCL2 inhibitor (Mesutoclax/ICP-248) is advancing two registration Phase III clinical studies in the hematological malignancies field [3] Collaboration and International Expansion - The partnership with Zenas BioPharma, established in October 2025, plans to initiate a global Phase III clinical trial for Obinutuzumab targeting secondary progressive multiple sclerosis (SPMS) in the first quarter of 2026; Zenas will also advance two preclinical molecules from Nocera Biopharma into clinical stages in 2026. The total potential value of this collaboration exceeds $2 billion, including milestone payments and royalties [4] Commercialization and Product Pipeline - Newly approved drugs, Tansimod (Mingnuokai) and Zolbetuximab (Yinuoxin), which were approved in 2025, are now on the market and expected to contribute to revenue growth alongside Obinutuzumab. The new indications for Obinutuzumab (such as first-line treatment for CLL/SLL) are anticipated to drive continued sales growth [5] - The company achieved profitability for the first time in 2025, with revenue of approximately 2.37 billion yuan and a net profit of about 630 million yuan. Management indicates that the company will enter a phase of sustainable profitability starting in 2025, focusing on global expansion and pipeline diversification to solidify performance [5]

Core Viewpoint - HaiChuang Pharmaceutical (688302) has made significant progress in commercialization, medical insurance access, and research pipeline, with revenue growth and reduced losses as indicated in its performance forecast [1] Group 1: Project Advancement - The company announced on February 1, 2026, that its soft capsule production line for the anti-tumor drug has passed GMP compliance inspection, indicating the core product, Deuteroenzalutamide soft capsules, is now capable of large-scale production, completing the "R&D - Production - Sales" full industry chain [2] Group 2: Business Progress - Deuteroenzalutamide soft capsules were included in the national medical insurance catalog on December 2025, effective from January 1, 2026, which is expected to enhance patient accessibility through a "direct sales + agency" dual-track model; the product was previously approved for market launch in May 2025 and included in the CSCO Prostate Cancer Diagnosis and Treatment Guidelines [3] Group 3: Product Development Progress - The company is focusing on prostate cancer and metabolic diseases, with the oral AR PROTAC drug HP518 having completed Phase I clinical trials, while Phase II trials in China and combination therapy studies are ongoing; HP515, aimed at treating metabolic-associated fatty liver disease (MASH), has entered Phase II clinical trials, with preclinical data on its combination with GLP-1 presented at international conferences [4] Group 4: Performance and Operations - The 2025 performance forecast indicates the company expects revenue between 19 million and 22 million, representing a significant year-on-year increase, with losses narrowing by 24.81% to 37.34%, primarily due to the sales of Deuteroenzalutamide [5] Group 5: Institutional Research - In January 2026, the company hosted a research meeting with 29 institutions, including Foresight Investment and Western Securities, reflecting market interest in its innovative drug pipeline [6]

业绩经营情况 公司预计2026年营收为7.96亿至8.29亿元，同比增长49.45%至55.55%，主要受益于重组人凝血酶医保放 量及吉卡西替尼商业化推进。 泽璟制药与艾伯维就ZG006药物达成全球开发及商业化协议，艾伯维获得大中华区以外独家权利；泽璟 已收到1亿美元首付款，并可能获得最高6000万美元近期里程碑付款及10.75亿美元远期里程碑付款。 ZG006针对小细胞肺癌和神经内分泌癌的临床试验数据显示，在II期剂量优化试验中，10mg组确认客观 缓解率（ORR）达53.3%，中位无进展生存期（mPFS）为7.03个月。 产品研发进展 除ZG006外，注射用ZG005在宫颈癌II期临床试验中确认ORR为40.9%，疾病控制率（DCR）68.2%；公 司多款候选药物如ZGGS18、ZGGS34等已进入中美I期临床阶段。 经济观察网 根据截至2026年2月14日的公开信息，泽璟制药-U（688266.SH）近期有以下事件值得关 注： 高管减持 公司公告称，股东ZELIN SHENG（盛泽林）拟减持不超过273,907股（占总股本0.1035%），股东宁波 泽奥拟减持不超过2,475,090股（占总股本0.93 ...

Core Viewpoint - Guangzhou Pharmaceutical Group Co., Ltd. has disclosed significant anti-corruption results in a recent annual report, highlighting the company's commitment to integrity and governance [1] Group 1: Anti-Corruption Measures - The report details 17 cases of corruption over the past year, with a total amount involved of approximately 170 million yuan [1] - Internal sources indicate that these cases have been communicated internally as warnings to staff [1] Group 2: Disciplinary Actions - In 2025, the disciplinary inspection and supervision agencies of Guangzhou Pharmaceutical Group and its subsidiaries investigated 30 individuals and imposed 42 party disciplinary and administrative penalties [1] - The 17 typical cases involved key personnel from major subsidiaries, including Zhongyi Pharmaceutical, Wanglaoji Pharmaceutical, Baiyunshan Pharmaceutical Factory, He Jigong Pharmaceutical Factory, and Huanhong Traditional Chinese Medicine [1]

康臣药业此前公告，于2025年6月13日，董事局决议执行股份回购计划，以资金总数不超过2亿港元为 限，于公开市场适时回购股份(先前股份回购计划)。于2026年1月29日，董事局决议根据购回授权进一 步执行另一项股份回购计划，以于公开市场适时回购股份，除先前股份回购计划的资金总数外，额外增 加最多1亿港元(股份回购计划)。据此股份回购计划合计拟动用资金总额将不超过3亿港元。股份回购计 划之期限自本公告日期起至公司下届股东周年大会结束时止或股东于股东大会上撤回或修订购回授权为 止。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中康臣药业(01681) 获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效， 届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，康臣药业有可能被调入港股通，因其 满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

来源：新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示，2026年2月14日，Corxel Pharmaceuticals, Inc.的注射用 JX10申请已获受理，受理号为JXHB2600019。 受理号JXHB2600019药品名称注射用JX10药品类型化药申请类型补充申请注册分类1企业名称Corxel Pharmaceuticals, Inc.;Fuji Yakuhin Co., Ltd;承办日期2026年2月14日 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 ...

Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 1.516 billion yuan, representing a year-on-year increase of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a significant year-on-year growth of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, which reflects a decrease of 6.01% compared to the previous year [1] - Total assets at the end of the reporting period reached 3.053 billion yuan, marking a year-on-year increase of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, up 13.44% year-on-year [1] Performance Drivers - The increase in revenue was primarily driven by growth in sales of formulation products, raw materials, intermediate products, and technical service income [2] - The rise in net profit attributable to the parent company was mainly influenced by investment income [2] - The decline in net profit after deducting non-recurring gains and losses was attributed to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit would have been 182 million yuan, an increase of 31.57% year-on-year [2] Significant Changes in Financial Metrics - Operating profit increased by 51.53% year-on-year, while total profit rose by 51.88% [3] - The basic earnings per share grew by 47.20% year-on-year, largely due to the strategic investment and restructuring of Shanghai Zhigen Pharmaceutical Technology Co., Ltd., which resulted in the company no longer consolidating it in its financial statements [3] - The company's share capital increased by 40.00% due to a capital reserve conversion, raising the total shares from 93.8 million to 131.32 million [3]

Group 1 - The company announced the resignation of its board secretary, Chen Yingge, due to personal reasons, effective immediately upon delivery of the resignation letter to the board [2] - The company will promptly initiate the process of appointing a new board secretary in accordance with relevant regulations and guidelines [2] - During the interim period before a new board secretary is appointed, Zhang Suya, a company director and senior management personnel, will assume the responsibilities of the board secretary [2] Group 2 - Chen Yingge did not hold any shares in the company at the time of her resignation and has fulfilled all responsibilities related to her position [2] - The board expressed gratitude for Chen Yingge's contributions to the company during her tenure, particularly in governance, information disclosure, and investor relations [2]

Group 1 - The company, Tianjin Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Tianjin Drug Administration for its subsidiary, Tianjin He Ping Pharmaceutical Co., Ltd. [1] - The inspection was conducted from November 25 to November 28, 2025, focusing on the production line for hormone eye drops [1][2] - The inspection concluded that the production line meets the requirements of the 2010 revised Good Manufacturing Practice (GMP) [2] Group 2 - The production line is the company's first for hormone eye drops, indicating that the company now has the capability to produce these products [2] - This development is expected to better meet market demand and ensure the supply of medications [2] - However, the actual sales performance post-production may be influenced by market environment changes, introducing a level of uncertainty [2]

Group 1 - The company, Shenzhen Xinlitai Pharmaceutical Co., Ltd., submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on February 12, 2026 [1][2] - The application materials were published on the Hong Kong Stock Exchange website and are subject to updates and revisions as required by the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1][2] - If the issuance and listing are implemented, the target investors will be limited to qualified foreign investors and domestic qualified investors authorized to conduct overseas securities investments according to Chinese laws and regulations [1][2] Group 2 - The announcement serves to inform domestic investors about the issuance and listing, and does not constitute an offer or invitation to purchase the H-shares [2] - The issuance and listing are subject to approvals from relevant government agencies and regulatory bodies, including the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating uncertainty in the process [2] - The company will fulfill its information disclosure obligations in accordance with the progress of the matter [2]